2024
Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis
Toljan K, Daboul L, Raza P, Martin M, Cao Q, O’Donnell C, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis. Multiple Sclerosis Journal 2024, 30: 1268-1277. PMID: 39234802, PMCID: PMC11421977, DOI: 10.1177/13524585241271988.Peer-Reviewed Original ResearchConceptsCentral vein signPositive predictive valueOligoclonal bandsDiagnostic performanceMS diagnosisCerebrospinal fluidMultiple sclerosisPredictive valueNegative predictive valueCerebrospinal fluid testingRadiological suspicionDiagnostic accuracyImaging biomarkersDiagnosisDiagnostic biomarkersMonthsSclerosisBiomarkersPilot studyBaselineSelection 3Meta-analysis identifies common gut microbiota associated with multiple sclerosis
Lin Q, Dorsett Y, Mirza A, Tremlett H, Piccio L, Longbrake E, Choileain S, Hafler D, Cox L, Weiner H, Yamamura T, Chen K, Wu Y, Zhou Y. Meta-analysis identifies common gut microbiota associated with multiple sclerosis. Genome Medicine 2024, 16: 94. PMID: 39085949, PMCID: PMC11293023, DOI: 10.1186/s13073-024-01364-x.Peer-Reviewed Original ResearchConceptsRRNA gene sequence dataGroups of microbial taxaGene sequence dataMicrobiome community structureAbundance of FaecalibacteriumAbundance of PrevotellaAbundance of ActinomycesSequence dataBeta diversityMicrobial taxaGut microbiotaMicrobial compositionCommunity structureNetwork analysisGutBacterial correlationsMicrobiotaAbundanceMultiple sclerosisDiverse groupMeta-analysisDiversityTaxaFaecalibacteriumConclusionsOur meta-analysis
2023
A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis
Daboul L, O’Donnell C, Amin M, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Prchkovska V, Raza P, Ramos M, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis. Multiple Sclerosis Journal 2023, 30: 25-34. PMID: 38088067, PMCID: PMC11037932, DOI: 10.1177/13524585231214360.Peer-Reviewed Original ResearchConceptsCentral vein signMultiple sclerosisPositive lesionsInter-rater agreementDiagnosis of MSMagnetic resonance imaging (MRI) biomarkersDiagnostic performancePossible multiple sclerosisInter-rater reliability assessmentGood diagnostic performanceMcDonald criteriaMulticenter studyVein assessmentMean ageVein signImaging biomarkersLesionsMRI sequencesCharacteristic curveSclerosisPatientsDiagnosisAssessmentParticipantsOptimal method
2022
Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.
Daboul L, O'Donnell CM, Cao Q, Amin M, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree BAC, Freeman L, Henry RG, Longbrake EE, Nakamura K, Oh J, Papinutto N, Pelletier D, Samudralwar RD, Suthiphosuwan S, Schindler MK, Sotirchos ES, Sicotte NL, Solomon AJ, Shinohara RT, Reich DS, Ontaneda D, Sati P. Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis. American Journal Of Roentgenology 2022, 220: 115-125. PMID: 35975888, PMCID: PMC10016223, DOI: 10.2214/ajr.22.27731.Peer-Reviewed Original ResearchConceptsWhite matter lesionsCentral vein signGBCA useMultiple sclerosisMS diagnosisVein signPostcontrast imagesGadolinium-based contrast agent administrationPilot study cohortDiagnostic performanceContrast agent administrationMcDonald criteriaInvestigational trialsStudy cohortMatter lesionsClinical dataClinical impactBrain MRIClinical practiceAgent administrationDiagnostic biomarkersMRI biomarkersPostcontrast FLAIRPrecontrast imagesSecondary analysisWorsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic
Levit E, Cohen I, Dahl M, Edwards K, Weinstock-Guttman B, Ishikawa T, Kavak K, Leavitt V, Nelson K, Onomichi K, Bar-Or A, Perrone C, Riley C, Venkatesh S, De Jager PL, Xia Z, Longbrake EE, Collaborative M. Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic. Multiple Sclerosis And Related Disorders 2022, 58: 103482. PMID: 35016114, PMCID: PMC8742609, DOI: 10.1016/j.msard.2021.103482.Peer-Reviewed Original ResearchConceptsPhysical functionDepression scoresCOVID-19 pandemicPhysical disabilityNeurological inflammatory diseasesMajor academic medical centerAcademic medical centerHigher baseline levelsLack of diseaseDisease durationStudy entryTherapy useNeuroinflammatory diseasesMale genderInflammatory diseasesPhysical functioningMedical CenterMood symptomsDepressive symptomsSmall cohortBaseline levelsSerial surveysSignificant depressionOlder ageWorse depression
2021
A New England COVID-19 Registry of Patients With CNS Demyelinating Disease
Money KM, Mahatoo A, Samaan S, Anand P, Baber U, Bailey M, Bakshi R, Bouley A, Bower A, Cahill J, Houtchens M, Katz J, Lathi E, Levit E, Longbrake EE, McAdams M, Napoli S, Raibagkar P, Wade P, Sloane JA. A New England COVID-19 Registry of Patients With CNS Demyelinating Disease. Neurology Neuroimmunology & Neuroinflammation 2021, 8: e1046. PMID: 34341094, PMCID: PMC8362350, DOI: 10.1212/nxi.0000000000001046.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionHospitalization ratesRisk factorsSevere coronavirus disease 2019 (COVID-19) infectionDisease-modifying therapy useCoronavirus disease 2019 (COVID-19) infectionStepwise multivariate logistic regressionCNS Demyelinating DiseaseNausea/vomitingAbsolute lymphocyte countIndependent risk factorNumber of comorbiditiesDisease 2019 infectionPatient risk factorsRisk of hospitalizationCOVID-19 cohortDisease-modifying therapiesCase fatality rateMultivariate logistic regressionCOVID-19 registryFisher's exact testDemyelinating diseaseClinical characteristicsLymphocyte countNeurologic symptomsManifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases
Levin SN, Venkatesh S, Nelson KE, Li Y, Aguerre I, Zhu W, Masown K, Rimmer KT, Diaconu CI, Onomichi KB, Leavitt VM, Levine LL, Strauss‐Farber R, Vargas WS, Banwell B, Bar‐Or A, Berger JR, Goodman AD, Longbrake EE, Oh J, Weinstock‐Guttman B, Thakur KT, Edwards KR, Riley CS, Xia Z, De Jager PL, Collaborative M. Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases. Annals Of Clinical And Translational Neurology 2021, 8: 918-928. PMID: 33616290, PMCID: PMC8013889, DOI: 10.1002/acn3.51314.Peer-Reviewed Original ResearchConceptsNeuroinflammatory disordersMultiple sclerosisCOVID-19Year-long prospective studyPotential risk factorsPatient reported experienceTesting shortagesNeurological disabilityLiver diseaseNeuroinflammatory diseasesTelemedicine visitsProspective studyPotential confoundersMS casesRisk factorsNeurological careSevere casesTreatment changesSymptom criteriaEarly changesMore depressionReference groupCase prevalenceDisease managementGreater likelihoodInfluence of immunomodulatory drugs on the gut microbiota
Cohen I, Ruff WE, Longbrake EE. Influence of immunomodulatory drugs on the gut microbiota. Translational Research 2021, 233: 144-161. PMID: 33515779, PMCID: PMC8184576, DOI: 10.1016/j.trsl.2021.01.009.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityCell ProliferationCytokinesFemaleGastrointestinal MicrobiomeHost Microbial InteractionsHumansImmune Checkpoint InhibitorsImmunity, InnateImmunity, MucosalImmunologic FactorsImmunomodulationLymphocytesMaleModels, ImmunologicalSex FactorsTranslational Research, BiomedicalConceptsImmune checkpoint inhibitorsGut microbiotaCheckpoint inhibitorsAutoimmune diseasesMainstay of treatmentType of immunotherapyInflammatory cytokine inhibitorComprehensive literature searchMechanism of actionImmunomodulatory medicationsDrug-induced shiftImmunomodulatory drugsCytokine inhibitorsImmunotherapy effectImmune cellsClinical significanceImmune responseMost immunotherapiesCommensal microbesDrug efficacyImmunotherapyLiterature searchAntiproliferative drugsMedicationsMicrobiota
2017
Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS
Baldassari LE, Salter AR, Longbrake EE, Cross AH, Naismith RT. Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS. Multiple Sclerosis Journal 2017, 24: 1347-1355. PMID: 28766993, DOI: 10.1177/1352458517721357.Peer-Reviewed Original ResearchConceptsDisability Status ScaleStatus ScaleClinical practiceExpanded Disability Status ScaleMultiple sclerosis clinical trialsMultiple sclerosis clinical practiceCross-sectional comparisonCombiRx trialDisability scoresClinical trialsPilot cohortEDSSClinical monitoringPatient careClinical settingPatientsTrialsDisabilityFunctional systemsUseful measureScoringStandard measuresCohortCareDimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
Longbrake EE, Cantoni C, Chahin S, Cignarella F, Cross AH, Piccio L. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count. Multiple Sclerosis Journal 2017, 24: 728-738. PMID: 28480794, PMCID: PMC5665729, DOI: 10.1177/1352458517707069.Peer-Reviewed Original ResearchConceptsAbsolute lymphocyte countDMF-treated patientsPeripheral blood mononuclear cellsDimethyl fumarateLymphocyte countPeptide stimulationLow absolute lymphocyte countFollicular T helper cellsDMF-induced lymphopeniaInvariant T (MAIT) cellsPro-inflammatory cytokinesT-cell phenotypeBlood mononuclear cellsT cell productionT helper cellsT lymphocyte functionMemory B cellsActivation-induced cell deathMultiparametric flow cytometryUntreated patientsMultiple sclerosisMononuclear cellsHealthy controlsT cellsT lymphocytes
2016
Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis
Longbrake EE, Lancia S, Tutlam N, Trinkaus K, Naismith RT. Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis. Multiple Sclerosis And Related Disorders 2016, 10: 198-203. PMID: 27919490, PMCID: PMC5392253, DOI: 10.1016/j.msard.2016.10.009.Peer-Reviewed Original ResearchConceptsRetinal nerve fiber layerOptic neuritisVisual dysfunctionMS patientsContrast chartsVisual fieldVFQ-25 scoresPelli-Robson contrast sensitivity chartNerve fiber layerSevere visual dysfunctionSnellen eye chartLow contrast chartsCross-sectional studyContrast sensitivity testQuality of lifeContrast sensitivity chartLow-contrast testsOptical coherence tomographyMultiple sclerosisVisual acuityElectrophysiologic functionPatientsEye chartPR chartNeuritisThe contemporary spectrum of multiple sclerosis misdiagnosis
Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG. The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology 2016, 87: 1393-1399. PMID: 27581217, PMCID: PMC5047038, DOI: 10.1212/wnl.0000000000003152.Peer-Reviewed Original ResearchConceptsMultiple sclerosisNeurologic symptomsMisdiagnosis of MSAcademic MS centersCorroborative objective evidenceMultiple sclerosis misdiagnosisDisease-modifying therapiesRadiographic diagnostic criteriaNonspecific neurologic symptomsMS therapyConsideration of symptomsCNS lesionsMRI abnormalitiesMS centersUnnecessary morbidityAlternate diagnosisMS attacksCorrect diagnosisDiagnostic criteriaPatientsMisdiagnosisObjective evidenceSymptomsTherapyDiagnosis
2013
Susac syndrome in a patient with human immunodeficiency virus infection
Longbrake EE, Ances BM, Viets RB, Clifford DB. Susac syndrome in a patient with human immunodeficiency virus infection. Journal Of NeuroVirology 2013, 19: 270-273. PMID: 23690260, PMCID: PMC4582780, DOI: 10.1007/s13365-013-0164-z.Peer-Reviewed Original Research
2008
Intra‐neural administration of fractalkine attenuates neuropathic pain‐related behaviour
Holmes FE, Arnott N, Vanderplank P, Kerr NC, Longbrake EE, Popovich PG, Imai T, Combadière C, Murphy PM, Wynick D. Intra‐neural administration of fractalkine attenuates neuropathic pain‐related behaviour. Journal Of Neurochemistry 2008, 106: 640-649. PMID: 18410510, PMCID: PMC2726982, DOI: 10.1111/j.1471-4159.2008.05419.x.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesicsAnimalsBehavior, AnimalChemokine CX3CL1CX3C Chemokine Receptor 1Disease Models, AnimalDose-Response Relationship, DrugGanglia, SpinalGene Expression RegulationMacrophagesMaleMiceMice, Inbred BALB CMice, KnockoutPain MeasurementPain ThresholdReaction TimeReceptors, ChemokineRNA, MessengerSciaticaSpinal CordTime FactorsConceptsDorsal root gangliaNeuropathic pain-related behaviorLumbar dorsal root gangliaBALB/c controlsDevelopment of allodyniaIntra-neural injectionSciatic nerve proximalNeuropathic pain statesNerve injury modelSciatic nerve axotomyPain-related behaviorsExpression of CX3CR1Site of injuryNumber of cytokinesNeuropathic painNerve axotomyPain statesNerve proximalRoot gangliaSciatic nerveInjury modelCX3CR1 mRNAFractalkine mRNAKnockout miceAxotomy